Protalix BioTherapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Protalix BioTherapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every $100 of reported profit came with $-100 of operating cash. Lower than 98% of Healthcare companies in United States.
- Growth Efficiency Ratio: Sales grew 11% in 3 years; of every extra $100 of sales, $163 became extra profit. Higher than 87% of Healthcare companies in United States.
- Cash Locked Ratio: For every $100 of sales, $45 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $30 tied up three years earlier. More money tied up than 87% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$-100Over the last 3 years, every $100 of reported profit came with $-100 of operating cash.
Lower than 98% of Healthcare companies in United States.
Self-Funding Ratio
-1.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 61% of Healthcare companies in United States.
Cash Locked Ratio
$45For every $100 of sales, $45 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $30 tied up three years earlier.
More money tied up than 87% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
$163Sales grew 11% in 3 years; of every extra $100 of sales, $163 became extra profit.
Higher than 87% of Healthcare companies in United States.
Asset Productivity Ratio
+11% / +48%In 3 years sales changed by +11% while total assets changed by +48%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-8.7×Operating cash was negative last year, while some debt falls due within a year.
Higher than 56% of Healthcare companies in United States.
Cash Cushion Ratio
+11%Cash, after subtracting all debt, equals 11% of its market value (net cash).
Higher than 51% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Protalix BioTherapeutics, Inc. owes $0.35 for every $1 it owns. Protalix BioTherapeutics, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
11.2Investors pay $11.2 for every $1 of Protalix BioTherapeutics, Inc.'s yearly profit, lower than 80% of Healthcare companies in United States.
P/B ratio
2.90The share price is 2.90 times Protalix BioTherapeutics, Inc.'s book value per share, higher than 54% of Healthcare companies in United States.
Market cap
$207 MThe total market value of all of Protalix BioTherapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 58% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$71 MWhat Protalix BioTherapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.89Net worth divided by the number of shares. The share price of $2.57 is 2.9 times this, which is the P/B above.
Return on equity (ROE)
31.2%Protalix BioTherapeutics, Inc. earned 31.2% on its shareholders' money over the last year, higher than 94% of Healthcare companies in United States.
Owes vs Owns
0.35×Protalix BioTherapeutics, Inc. owes $0.35 for every $1 it owns (low), lower than 55% of Healthcare companies in United States.
Dividend yield
NoneProtalix BioTherapeutics, Inc. does not currently pay a dividend.
Revenue growth
-1%Revenue fell 1% in the year to Dec 2025, and grew 3% a year on average over 3 years.
Profit growth
LossProtalix BioTherapeutics, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Profit margin
-12.5%Protalix BioTherapeutics, Inc. lost $13 for every $100 of revenue.
Interest cover
Not coveredProtalix BioTherapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashProtalix BioTherapeutics, Inc. held $22 M more cash than debt (net cash) at Dec 2025.
Questions
What is Protalix BioTherapeutics, Inc.'s P/E ratio?
Investors pay $11.2 for every $1 of Protalix BioTherapeutics, Inc.'s yearly profit, lower than 80% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Protalix BioTherapeutics, Inc.: $207 M ÷ $71 M (30 Jun 2026) = 2.9.
What is Protalix BioTherapeutics, Inc.'s return on equity?
Protalix BioTherapeutics, Inc. earned 31.2% on its shareholders' money over the last year, higher than 94% of Healthcare companies in United States.
How much does Protalix BioTherapeutics, Inc. owe compared with what it owns?
Protalix BioTherapeutics, Inc. owes $0.35 for every $1 it owns (low), lower than 55% of Healthcare companies in United States.
Does Protalix BioTherapeutics, Inc. pay a dividend?
No. Protalix BioTherapeutics, Inc. does not currently pay a dividend.
Is Protalix BioTherapeutics, Inc.'s revenue growing?
Revenue fell 1% in the year to Dec 2025, and grew 3% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.